InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc

Bullboard Posts

Comment by Moneymagnet14on Jun 08, 2014 1:39pm

181 Views

Post# 22641138

RE:RE:INTERESTING R&D

Here's a couple links to some Youtube video's that show how crazy Jim Cramer is about GW Pharma, I really do feel once this story resonates with U.S Investors this company could take a life of its own. I would imagine anyone that could have invested in GW Pharma 5 years ago and potentially could have bought it at 66 Cents would definitely set a small percentage aside from their portfolio to do so.

Anyways here's several Links on Jim Cramer and his outlook on GWPH.